Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT
The role of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in the treatment of myeloma (MM) patients with severe and/or dialysis-dependent renal impairment remains uncertain. We report on the outcomes of 110 patients (median age 57 years) who had become dialysis-depen...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2023-04, Vol.58 (4), p.424-429 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 429 |
|---|---|
| container_issue | 4 |
| container_start_page | 424 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 58 |
| creator | Waszczuk-Gajda, Anna Gras, Luuk de Wreede, Liesbeth C. Sirait, Tiarlan Illes, Arpad Ozkurt, Zubeyde Nur Snowden, John A. Arat, Mutlu Bulabois, Claude Eric Niederland, Judith Sever, Matjaz Paneesha, Shankara Potter, Victoria Gadisseur, Alain Chalopin, Thomas Van Gorkom, Gwendolyn López, Joaquin Martínez Kerre, Tessa Drozd-Sokolowska, Joanna Raj, Kavita Hayden, Patrick J. Beksac, Meral Yakoub-Agha, Ibrahim McLornan, Donal P. Schönland, Stefan |
| description | The role of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in the treatment of myeloma (MM) patients with severe and/or dialysis-dependent renal impairment remains uncertain. We report on the outcomes of 110 patients (median age 57 years) who had become dialysis-dependent pre-ASCT and who underwent a first ASCT between 1997 and 2017. Sixty-three (57%) patients had light chain MM. All patients required dialysis (94% hemodialysis and 6% peritoneal). Forty-four of 71 (62%) patients received bortezomib-based induction regimens and 42 (39%) patients had achieved at least a very good partial response (VGPR) pre-ASCT. Melphalan dosing was as follows: ≤140 mg/m
2
(82%), and >140 mg/m
2
(18%). The median PFS after ASCT was 35 months (95% CI: 21.5–42.2) and the median OS 102 months (95% CI: 70.4–129.1). At 1, 2, and 5 years after ASCT, 8% (95% CI 3–14%), 13% (6–20%), and 20% (12–29%) of patients, respectively, had achieved dialysis independence. In multivariate analyses of OS and PFS including age at ASCT, response at ASCT, and year of ASCT, younger age at ASCT and better response at ASCT (CR/VGPR/PR vs. MR/SD/progression) were significantly associated with better OS and PFS. |
| doi_str_mv | 10.1038/s41409-023-01915-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04489832v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2795095172</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-63dfc1b5620f7b48ebb369eb9c8802c0cb562a34986884678e04a8b725c213e73</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhSMEokPhBVggS2xgEfBfbGc5bQdaaSoWDGvLcZwZl8QebAeUHQ_Ba_BSPAlOU4rEgpXlez-fe31OUTxH8A2CRLyNFFFYlxCTEqIaVSV_UKwQ5aysCKseFiuImSgJYfVJ8STGGwgRpbB6XJwQxgTivFoVPz-qzqQJKNcC03VWKz0B3wE1Jt_7vR8jiMkMQJu-BykoF4-9ckkl6x2wDrRW9VO0sWzN0bjWuASGyfR-UOCYoXyPv77_2B0MuLhaX2yus9rYTqALfgApV_UheGc1GFRv9045bU0E33z4bN0-K4R0u81Mbs6ud0-LR53qo3l2d54Wn95tdueX5fbD-6vz9bbU2ZBUMtJ2GjUVw7DjDRWmabIJpqm1EBBrqOeWIrQWTAjKuDCQKtFwXGmMiOHktHi96B5UL4_BDipM0isrL9dbOdcgpaIWBH9FmX21sMfgv4wmJjnYONulnMn2ScyZwKSueZ3Rl_-gN34MLv8kU3UF6wpxnCm8UDr4GIPp7jdAUM7ByyV4mYOXt8HLeeMXd9JjM5j2_smfpDNAFiDmltub8Hf2f2R_Ax6Kuww</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2795095172</pqid></control><display><type>article</type><title>Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT</title><source>MEDLINE</source><source>Springer Online Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Waszczuk-Gajda, Anna ; Gras, Luuk ; de Wreede, Liesbeth C. ; Sirait, Tiarlan ; Illes, Arpad ; Ozkurt, Zubeyde Nur ; Snowden, John A. ; Arat, Mutlu ; Bulabois, Claude Eric ; Niederland, Judith ; Sever, Matjaz ; Paneesha, Shankara ; Potter, Victoria ; Gadisseur, Alain ; Chalopin, Thomas ; Van Gorkom, Gwendolyn ; López, Joaquin Martínez ; Kerre, Tessa ; Drozd-Sokolowska, Joanna ; Raj, Kavita ; Hayden, Patrick J. ; Beksac, Meral ; Yakoub-Agha, Ibrahim ; McLornan, Donal P. ; Schönland, Stefan</creator><creatorcontrib>Waszczuk-Gajda, Anna ; Gras, Luuk ; de Wreede, Liesbeth C. ; Sirait, Tiarlan ; Illes, Arpad ; Ozkurt, Zubeyde Nur ; Snowden, John A. ; Arat, Mutlu ; Bulabois, Claude Eric ; Niederland, Judith ; Sever, Matjaz ; Paneesha, Shankara ; Potter, Victoria ; Gadisseur, Alain ; Chalopin, Thomas ; Van Gorkom, Gwendolyn ; López, Joaquin Martínez ; Kerre, Tessa ; Drozd-Sokolowska, Joanna ; Raj, Kavita ; Hayden, Patrick J. ; Beksac, Meral ; Yakoub-Agha, Ibrahim ; McLornan, Donal P. ; Schönland, Stefan</creatorcontrib><description>The role of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in the treatment of myeloma (MM) patients with severe and/or dialysis-dependent renal impairment remains uncertain. We report on the outcomes of 110 patients (median age 57 years) who had become dialysis-dependent pre-ASCT and who underwent a first ASCT between 1997 and 2017. Sixty-three (57%) patients had light chain MM. All patients required dialysis (94% hemodialysis and 6% peritoneal). Forty-four of 71 (62%) patients received bortezomib-based induction regimens and 42 (39%) patients had achieved at least a very good partial response (VGPR) pre-ASCT. Melphalan dosing was as follows: ≤140 mg/m
2
(82%), and >140 mg/m
2
(18%). The median PFS after ASCT was 35 months (95% CI: 21.5–42.2) and the median OS 102 months (95% CI: 70.4–129.1). At 1, 2, and 5 years after ASCT, 8% (95% CI 3–14%), 13% (6–20%), and 20% (12–29%) of patients, respectively, had achieved dialysis independence. In multivariate analyses of OS and PFS including age at ASCT, response at ASCT, and year of ASCT, younger age at ASCT and better response at ASCT (CR/VGPR/PR vs. MR/SD/progression) were significantly associated with better OS and PFS.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/s41409-023-01915-7</identifier><identifier>PMID: 36681775</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/699/1541/1990/804 ; 692/700/565/2319 ; Age ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Autografts ; Bortezomib ; Bortezomib - therapeutic use ; Cell Biology ; Chemotherapy ; Dialysis ; Dosage ; Hematology ; Hematopoietic Stem Cell Transplantation ; Hemodialysis ; Humans ; Internal Medicine ; Life Sciences ; Malignancy ; Medicine ; Medicine & Public Health ; Melphalan ; Middle Aged ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Myeloma ; Public Health ; Renal Dialysis ; Renal function ; Retrospective Studies ; Stem Cell Transplantation ; Stem Cells ; Transplantation ; Transplantation, Autologous ; Treatment Outcome</subject><ispartof>Bone marrow transplantation (Basingstoke), 2023-04, Vol.58 (4), p.424-429</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Nature Limited.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-63dfc1b5620f7b48ebb369eb9c8802c0cb562a34986884678e04a8b725c213e73</citedby><cites>FETCH-LOGICAL-c409t-63dfc1b5620f7b48ebb369eb9c8802c0cb562a34986884678e04a8b725c213e73</cites><orcidid>0000-0003-1374-4503 ; 0000-0002-4853-5579 ; 0000-0002-8258-354X ; 0000-0003-2039-8557 ; 0000-0003-4524-8782 ; 0000-0003-1224-091X ; 0000-0001-6819-3476 ; 0000-0002-4562-6264 ; 0000-0002-7667-9369</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41409-023-01915-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41409-023-01915-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36681775$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lille.fr/hal-04489832$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Waszczuk-Gajda, Anna</creatorcontrib><creatorcontrib>Gras, Luuk</creatorcontrib><creatorcontrib>de Wreede, Liesbeth C.</creatorcontrib><creatorcontrib>Sirait, Tiarlan</creatorcontrib><creatorcontrib>Illes, Arpad</creatorcontrib><creatorcontrib>Ozkurt, Zubeyde Nur</creatorcontrib><creatorcontrib>Snowden, John A.</creatorcontrib><creatorcontrib>Arat, Mutlu</creatorcontrib><creatorcontrib>Bulabois, Claude Eric</creatorcontrib><creatorcontrib>Niederland, Judith</creatorcontrib><creatorcontrib>Sever, Matjaz</creatorcontrib><creatorcontrib>Paneesha, Shankara</creatorcontrib><creatorcontrib>Potter, Victoria</creatorcontrib><creatorcontrib>Gadisseur, Alain</creatorcontrib><creatorcontrib>Chalopin, Thomas</creatorcontrib><creatorcontrib>Van Gorkom, Gwendolyn</creatorcontrib><creatorcontrib>López, Joaquin Martínez</creatorcontrib><creatorcontrib>Kerre, Tessa</creatorcontrib><creatorcontrib>Drozd-Sokolowska, Joanna</creatorcontrib><creatorcontrib>Raj, Kavita</creatorcontrib><creatorcontrib>Hayden, Patrick J.</creatorcontrib><creatorcontrib>Beksac, Meral</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><creatorcontrib>McLornan, Donal P.</creatorcontrib><creatorcontrib>Schönland, Stefan</creatorcontrib><title>Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><addtitle>Bone Marrow Transplant</addtitle><description>The role of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in the treatment of myeloma (MM) patients with severe and/or dialysis-dependent renal impairment remains uncertain. We report on the outcomes of 110 patients (median age 57 years) who had become dialysis-dependent pre-ASCT and who underwent a first ASCT between 1997 and 2017. Sixty-three (57%) patients had light chain MM. All patients required dialysis (94% hemodialysis and 6% peritoneal). Forty-four of 71 (62%) patients received bortezomib-based induction regimens and 42 (39%) patients had achieved at least a very good partial response (VGPR) pre-ASCT. Melphalan dosing was as follows: ≤140 mg/m
2
(82%), and >140 mg/m
2
(18%). The median PFS after ASCT was 35 months (95% CI: 21.5–42.2) and the median OS 102 months (95% CI: 70.4–129.1). At 1, 2, and 5 years after ASCT, 8% (95% CI 3–14%), 13% (6–20%), and 20% (12–29%) of patients, respectively, had achieved dialysis independence. In multivariate analyses of OS and PFS including age at ASCT, response at ASCT, and year of ASCT, younger age at ASCT and better response at ASCT (CR/VGPR/PR vs. MR/SD/progression) were significantly associated with better OS and PFS.</description><subject>692/699/1541/1990/804</subject><subject>692/700/565/2319</subject><subject>Age</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Autografts</subject><subject>Bortezomib</subject><subject>Bortezomib - therapeutic use</subject><subject>Cell Biology</subject><subject>Chemotherapy</subject><subject>Dialysis</subject><subject>Dosage</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Life Sciences</subject><subject>Malignancy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melphalan</subject><subject>Middle Aged</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Myeloma</subject><subject>Public Health</subject><subject>Renal Dialysis</subject><subject>Renal function</subject><subject>Retrospective Studies</subject><subject>Stem Cell Transplantation</subject><subject>Stem Cells</subject><subject>Transplantation</subject><subject>Transplantation, Autologous</subject><subject>Treatment Outcome</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc1u1DAUhSMEokPhBVggS2xgEfBfbGc5bQdaaSoWDGvLcZwZl8QebAeUHQ_Ba_BSPAlOU4rEgpXlez-fe31OUTxH8A2CRLyNFFFYlxCTEqIaVSV_UKwQ5aysCKseFiuImSgJYfVJ8STGGwgRpbB6XJwQxgTivFoVPz-qzqQJKNcC03VWKz0B3wE1Jt_7vR8jiMkMQJu-BykoF4-9ckkl6x2wDrRW9VO0sWzN0bjWuASGyfR-UOCYoXyPv77_2B0MuLhaX2yus9rYTqALfgApV_UheGc1GFRv9045bU0E33z4bN0-K4R0u81Mbs6ud0-LR53qo3l2d54Wn95tdueX5fbD-6vz9bbU2ZBUMtJ2GjUVw7DjDRWmabIJpqm1EBBrqOeWIrQWTAjKuDCQKtFwXGmMiOHktHi96B5UL4_BDipM0isrL9dbOdcgpaIWBH9FmX21sMfgv4wmJjnYONulnMn2ScyZwKSueZ3Rl_-gN34MLv8kU3UF6wpxnCm8UDr4GIPp7jdAUM7ByyV4mYOXt8HLeeMXd9JjM5j2_smfpDNAFiDmltub8Hf2f2R_Ax6Kuww</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Waszczuk-Gajda, Anna</creator><creator>Gras, Luuk</creator><creator>de Wreede, Liesbeth C.</creator><creator>Sirait, Tiarlan</creator><creator>Illes, Arpad</creator><creator>Ozkurt, Zubeyde Nur</creator><creator>Snowden, John A.</creator><creator>Arat, Mutlu</creator><creator>Bulabois, Claude Eric</creator><creator>Niederland, Judith</creator><creator>Sever, Matjaz</creator><creator>Paneesha, Shankara</creator><creator>Potter, Victoria</creator><creator>Gadisseur, Alain</creator><creator>Chalopin, Thomas</creator><creator>Van Gorkom, Gwendolyn</creator><creator>López, Joaquin Martínez</creator><creator>Kerre, Tessa</creator><creator>Drozd-Sokolowska, Joanna</creator><creator>Raj, Kavita</creator><creator>Hayden, Patrick J.</creator><creator>Beksac, Meral</creator><creator>Yakoub-Agha, Ibrahim</creator><creator>McLornan, Donal P.</creator><creator>Schönland, Stefan</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-1374-4503</orcidid><orcidid>https://orcid.org/0000-0002-4853-5579</orcidid><orcidid>https://orcid.org/0000-0002-8258-354X</orcidid><orcidid>https://orcid.org/0000-0003-2039-8557</orcidid><orcidid>https://orcid.org/0000-0003-4524-8782</orcidid><orcidid>https://orcid.org/0000-0003-1224-091X</orcidid><orcidid>https://orcid.org/0000-0001-6819-3476</orcidid><orcidid>https://orcid.org/0000-0002-4562-6264</orcidid><orcidid>https://orcid.org/0000-0002-7667-9369</orcidid></search><sort><creationdate>20230401</creationdate><title>Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT</title><author>Waszczuk-Gajda, Anna ; Gras, Luuk ; de Wreede, Liesbeth C. ; Sirait, Tiarlan ; Illes, Arpad ; Ozkurt, Zubeyde Nur ; Snowden, John A. ; Arat, Mutlu ; Bulabois, Claude Eric ; Niederland, Judith ; Sever, Matjaz ; Paneesha, Shankara ; Potter, Victoria ; Gadisseur, Alain ; Chalopin, Thomas ; Van Gorkom, Gwendolyn ; López, Joaquin Martínez ; Kerre, Tessa ; Drozd-Sokolowska, Joanna ; Raj, Kavita ; Hayden, Patrick J. ; Beksac, Meral ; Yakoub-Agha, Ibrahim ; McLornan, Donal P. ; Schönland, Stefan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-63dfc1b5620f7b48ebb369eb9c8802c0cb562a34986884678e04a8b725c213e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>692/699/1541/1990/804</topic><topic>692/700/565/2319</topic><topic>Age</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Autografts</topic><topic>Bortezomib</topic><topic>Bortezomib - therapeutic use</topic><topic>Cell Biology</topic><topic>Chemotherapy</topic><topic>Dialysis</topic><topic>Dosage</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Life Sciences</topic><topic>Malignancy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melphalan</topic><topic>Middle Aged</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Myeloma</topic><topic>Public Health</topic><topic>Renal Dialysis</topic><topic>Renal function</topic><topic>Retrospective Studies</topic><topic>Stem Cell Transplantation</topic><topic>Stem Cells</topic><topic>Transplantation</topic><topic>Transplantation, Autologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Waszczuk-Gajda, Anna</creatorcontrib><creatorcontrib>Gras, Luuk</creatorcontrib><creatorcontrib>de Wreede, Liesbeth C.</creatorcontrib><creatorcontrib>Sirait, Tiarlan</creatorcontrib><creatorcontrib>Illes, Arpad</creatorcontrib><creatorcontrib>Ozkurt, Zubeyde Nur</creatorcontrib><creatorcontrib>Snowden, John A.</creatorcontrib><creatorcontrib>Arat, Mutlu</creatorcontrib><creatorcontrib>Bulabois, Claude Eric</creatorcontrib><creatorcontrib>Niederland, Judith</creatorcontrib><creatorcontrib>Sever, Matjaz</creatorcontrib><creatorcontrib>Paneesha, Shankara</creatorcontrib><creatorcontrib>Potter, Victoria</creatorcontrib><creatorcontrib>Gadisseur, Alain</creatorcontrib><creatorcontrib>Chalopin, Thomas</creatorcontrib><creatorcontrib>Van Gorkom, Gwendolyn</creatorcontrib><creatorcontrib>López, Joaquin Martínez</creatorcontrib><creatorcontrib>Kerre, Tessa</creatorcontrib><creatorcontrib>Drozd-Sokolowska, Joanna</creatorcontrib><creatorcontrib>Raj, Kavita</creatorcontrib><creatorcontrib>Hayden, Patrick J.</creatorcontrib><creatorcontrib>Beksac, Meral</creatorcontrib><creatorcontrib>Yakoub-Agha, Ibrahim</creatorcontrib><creatorcontrib>McLornan, Donal P.</creatorcontrib><creatorcontrib>Schönland, Stefan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Waszczuk-Gajda, Anna</au><au>Gras, Luuk</au><au>de Wreede, Liesbeth C.</au><au>Sirait, Tiarlan</au><au>Illes, Arpad</au><au>Ozkurt, Zubeyde Nur</au><au>Snowden, John A.</au><au>Arat, Mutlu</au><au>Bulabois, Claude Eric</au><au>Niederland, Judith</au><au>Sever, Matjaz</au><au>Paneesha, Shankara</au><au>Potter, Victoria</au><au>Gadisseur, Alain</au><au>Chalopin, Thomas</au><au>Van Gorkom, Gwendolyn</au><au>López, Joaquin Martínez</au><au>Kerre, Tessa</au><au>Drozd-Sokolowska, Joanna</au><au>Raj, Kavita</au><au>Hayden, Patrick J.</au><au>Beksac, Meral</au><au>Yakoub-Agha, Ibrahim</au><au>McLornan, Donal P.</au><au>Schönland, Stefan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><stitle>Bone Marrow Transplant</stitle><addtitle>Bone Marrow Transplant</addtitle><date>2023-04-01</date><risdate>2023</risdate><volume>58</volume><issue>4</issue><spage>424</spage><epage>429</epage><pages>424-429</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><abstract>The role of high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) in the treatment of myeloma (MM) patients with severe and/or dialysis-dependent renal impairment remains uncertain. We report on the outcomes of 110 patients (median age 57 years) who had become dialysis-dependent pre-ASCT and who underwent a first ASCT between 1997 and 2017. Sixty-three (57%) patients had light chain MM. All patients required dialysis (94% hemodialysis and 6% peritoneal). Forty-four of 71 (62%) patients received bortezomib-based induction regimens and 42 (39%) patients had achieved at least a very good partial response (VGPR) pre-ASCT. Melphalan dosing was as follows: ≤140 mg/m
2
(82%), and >140 mg/m
2
(18%). The median PFS after ASCT was 35 months (95% CI: 21.5–42.2) and the median OS 102 months (95% CI: 70.4–129.1). At 1, 2, and 5 years after ASCT, 8% (95% CI 3–14%), 13% (6–20%), and 20% (12–29%) of patients, respectively, had achieved dialysis independence. In multivariate analyses of OS and PFS including age at ASCT, response at ASCT, and year of ASCT, younger age at ASCT and better response at ASCT (CR/VGPR/PR vs. MR/SD/progression) were significantly associated with better OS and PFS.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>36681775</pmid><doi>10.1038/s41409-023-01915-7</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-1374-4503</orcidid><orcidid>https://orcid.org/0000-0002-4853-5579</orcidid><orcidid>https://orcid.org/0000-0002-8258-354X</orcidid><orcidid>https://orcid.org/0000-0003-2039-8557</orcidid><orcidid>https://orcid.org/0000-0003-4524-8782</orcidid><orcidid>https://orcid.org/0000-0003-1224-091X</orcidid><orcidid>https://orcid.org/0000-0001-6819-3476</orcidid><orcidid>https://orcid.org/0000-0002-4562-6264</orcidid><orcidid>https://orcid.org/0000-0002-7667-9369</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2023-04, Vol.58 (4), p.424-429 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04489832v1 |
| source | MEDLINE; Springer Online Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | 692/699/1541/1990/804 692/700/565/2319 Age Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autografts Bortezomib Bortezomib - therapeutic use Cell Biology Chemotherapy Dialysis Dosage Hematology Hematopoietic Stem Cell Transplantation Hemodialysis Humans Internal Medicine Life Sciences Malignancy Medicine Medicine & Public Health Melphalan Middle Aged Multiple myeloma Multiple Myeloma - drug therapy Myeloma Public Health Renal Dialysis Renal function Retrospective Studies Stem Cell Transplantation Stem Cells Transplantation Transplantation, Autologous Treatment Outcome |
| title | Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T15%3A05%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20efficacy%20of%20autologous%20stem%20cell%20transplantation%20in%20dialysis-dependent%20myeloma%20patients%E2%80%94The%20DIADEM%20study%20from%20the%20chronic%20malignancies%20working%20party%20of%20the%20EBMT&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=Waszczuk-Gajda,%20Anna&rft.date=2023-04-01&rft.volume=58&rft.issue=4&rft.spage=424&rft.epage=429&rft.pages=424-429&rft.issn=0268-3369&rft.eissn=1476-5365&rft_id=info:doi/10.1038/s41409-023-01915-7&rft_dat=%3Cproquest_hal_p%3E2795095172%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2795095172&rft_id=info:pmid/36681775&rfr_iscdi=true |